137 related articles for article (PubMed ID: 2610172)
1. [Pancreatic secretory trypsin inhibitor in urothelial cancer].
Tashiro K; Torii S; Iwamuro S; Ohishi Y; Hasegawa N; Kawashima Y; Mochizuki A; Yoshigoe H; Wada T; Machida T
Hinyokika Kiyo; 1989 Oct; 35(10):1659-63. PubMed ID: 2610172
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
3. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
4. [Recurrent urothelial cancer after resection of ureteral carcinoma].
Kong C; Ci J; Liu T
Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):465-7. PubMed ID: 10920948
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
David KA; Mallin K; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
Cancer; 2009 Apr; 115(7):1435-47. PubMed ID: 19215030
[TBL] [Abstract][Full Text] [Related]
6. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
7. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.
Isbarn H; Jeldres C; Shariat SF; Liberman D; Sun M; Lughezzani G; Widmer H; Arjane P; Pharand D; Fisch M; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
J Urol; 2009 Nov; 182(5):2177-81. PubMed ID: 19758662
[TBL] [Abstract][Full Text] [Related]
8. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
11. [A clinical study of renal pelvic and ureteral cancer associated with bladder cancer].
Sakaue K; Kakimoto K; Oda M; Kajikawa J; Koide T; Kobayashi Y
Hinyokika Kiyo; 1996 Feb; 42(2):91-4. PubMed ID: 8712094
[TBL] [Abstract][Full Text] [Related]
12. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
[TBL] [Abstract][Full Text] [Related]
13. [A clinicopathological study on carcinoma of the renal pelvis and ureter].
Hashimoto H; Saga Y; Tokumitsu M; Yamaguchi S; Morikawa M; Yachiku S
Hinyokika Kiyo; 1997 Oct; 43(10):707-12. PubMed ID: 9395905
[TBL] [Abstract][Full Text] [Related]
14. [A clinical study of tumor of the renal pelvis and ureter].
Kawashima K; Nakata S; Shimizu N; Matsuo Y; Imai K; Kobayashi M; Umeyama T; Saruki K; Yamanaka H; Suzuki K
Hinyokika Kiyo; 1988 Mar; 34(3):429-35. PubMed ID: 3389289
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
[TBL] [Abstract][Full Text] [Related]
16. Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry.
Lopez-Beltran A; Requena MJ; Alvarez-Kindelan J; Quintero A; Blanca A; Montironi R
J Clin Pathol; 2007 Mar; 60(3):332-5. PubMed ID: 16882698
[TBL] [Abstract][Full Text] [Related]
17. Unusual clinical presentation of upper urothelial carcinoma in Taiwan.
Chou YH; Huang CH
Cancer; 1999 Mar; 85(6):1342-4. PubMed ID: 10189140
[TBL] [Abstract][Full Text] [Related]
18. [A clinicopathological study on tumor of the renal pelvis and ureter].
Yoneda F; Kan M; Tsujimura H; Nakajima M; Furuya K; Tao S
Hinyokika Kiyo; 1989 Oct; 35(10):1665-71. PubMed ID: 2610173
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
[TBL] [Abstract][Full Text] [Related]
20. [Urothelial cancer of the upper urinary tract].
Jurincic-Winkler C; Horlbeck R; Gasser A; Glenewinkel J; Klippel KF
Urologe A; 1993 Jul; 32(4):295-9. PubMed ID: 8372411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
